Of 4 million continuously enrolled members, 4753 met MS criteria and had a DMD in year 0, of whom 2859 (60.2%) were adherent and 1894 (39.8%) were not adherent over years 1 to 3. Over the 3 years, 520 (18.2%) of the adherent and 471 (25.2%) of the not adherent had a moderate or severe relapse (relapse among adherent odds ratio 0.672, 95% confidence interval 0.584 to 0.774).
Findings:
• Prime found the average allowed medical expense per MS relapse was $9,000.
• MS DMD therapy adherence for 3 years was associated with a 7 percentage point decrease in members with claims indicating an MS relapse. • To prevent relapse in 1 MS member saving $9,000 in medical costs, 15 members currently non-adherent to DMD therapy for three years would need to be adherent. • It will cost $3 million in new DMD expenditures to get 15 members adherent.
Conclusion:
An investment of $333 in MS DMD cost is needed to save $1 in direct medical MS relapse cost avoided. This information helps inform clinical program and pharmaceutical value-based contracting assessments.
